5 studies found for:    21561347 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma
Intervention: Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine
2 Recruiting Intraoperative Radiation Therapy for Resectable Pancreas Cancer
Condition: Pancreas Cancer
Interventions: Radiation: 10 Gy Low-KV IORT;   Radiation: 15 Gy Low-KV IORT;   Radiation: 20 GY Low-KV IORT
3 Active, not recruiting Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Irinotecan
4 Active, not recruiting Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: FOLFIRINOX;   Genetic: Immunohistochemistry (IHC) Analysis;   Drug: Metformin;   Drug: mFOLFIRI
5 Unknown  Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin

Indicates status has not been verified in more than two years